News

REGN Q2 Deep Dive: New Indications and Pipeline Progress Offset EYLEA Challenges

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 3.6% ...

5 Insightful Analyst Questions From Regeneron’s Q2 Earnings Call

Regeneron’s second quarter was marked by robust growth in key products, which the company attributed to the strong commercial ...

Regeneron: EYLEA's Decline Is Masking A Deep Value Opportunity

Moving on, Regeneron’s second-quarter report was largely positive. Total revenues of $3.68 billion (up 4% YoY) beat analyst ...

Biohaven Reports Second Quarter 2025 Financial Results and Recent Business Developments

Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat ...
Labiotech.eu1d

Injecting hope into skin cancer treatment: The promise of melanoma vaccines

Discover how melanoma vaccines are gaining traction in the clinic and could soon become a treatment option for this deadly ...
pharmaphorum4d

FDA sets Feb decision date for Libtayo lung cancer challenge to ...

The FDA has started a priority review of Regeneron and Sanofi’s checkpoint inhibitor Libtayo in first-line non-small cell lung cancer (NSCLC), based on data they hope will carve out a niche for ...
Stocktwits on MSN3d

This Stock Has Tumbled 50% In One Year, Gets A Price Target Cut Today – But Retail Believes $400-450 Is A Good Entry Point

Truist on Monday lowered its price target on Regeneron (REGN) to $812 from $940, citing concerns with the company’s Eylea ...